More than 140 scientific studies suggest melatonin is a useful agent for treating SARS- CoV-2, according to research published in Cellular and Molecular Life Sciences.
Melatonin was most often researched for its ability to suppress inflammation and the cytokine storm related to COVID-19.
When people with COVID-19 were given melatonin, either alone or in combination with other treatments, severity of infection was reduced, death rate was lowered and hospitalizations were shortened.
Early on during the pandemic, a number of physicians and researchers called for melatonin in the treatment of COVID-19, but it was largely ignored.
Since melatonin is nonpatentable and inexpensive, there was little interest from the pharmaceutical industry or their government counterparts in promoting this compound.